These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 4644162)
21. Total and capillary fingertip blood flow in Raynaud's phenomenon. Coffman JD; Cohen AS N Engl J Med; 1971 Jul; 285(5):259-63. PubMed ID: 5090397 [No Abstract] [Full Text] [Related]
22. [Reserpine administration by retrograde intravenous route in patients with Raynaud's phenomenon]. Acevedo A; Arinoviche R; Palma A; Olea E; Guzmán G; Arriagada M; Grisanti M; Testar R Rev Med Chil; 1982 Nov; 110(11):1063-5. PubMed ID: 7184095 [No Abstract] [Full Text] [Related]
23. [Pathophysiology and medical treatment of Raynaud's phenomena]. Adar R Harefuah; 1973 Feb; 84(4):227-8. PubMed ID: 4574182 [No Abstract] [Full Text] [Related]
29. Treatment of patients with secondary Raynaud's syndrome. Ehrly AM Acta Chir Scand Suppl; 1976; 465():92-5. PubMed ID: 1069443 [TBL] [Abstract][Full Text] [Related]
30. Reserpine in Raynaud's disease and phenomenon. Short-term response to intra-arterial injection. Willerson JT; Thompson RH; Hookman P; Herdt J; Decker JL Ann Intern Med; 1970 Jan; 72(1):17-27. PubMed ID: 5410395 [No Abstract] [Full Text] [Related]
31. Medical uses of intra-arterial injections of reserpine. Treatment of Raynaud syndrome and of some vascular insufficiencies of the lower extremities. Tindall JP; Whalen RE; Burton EE Arch Dermatol; 1974 Aug; 110(2):233-7. PubMed ID: 4604746 [No Abstract] [Full Text] [Related]
32. [Value and limitations of venous blocks using reserpine in acrosyndromes of the upper extremities]. Serise JM; Gironnet I; Dugrais G; Janvier G; Winnock S; Boissiéras P J Mal Vasc; 1984; 9(2):107-9. PubMed ID: 6747471 [TBL] [Abstract][Full Text] [Related]
33. Minipress treatment of primary Raynaud's disease. Bodolay E; Hatvani I; Szegedi G Ther Hung; 1986; 34(2):96-101. PubMed ID: 3449974 [No Abstract] [Full Text] [Related]
35. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Kahan A; Amor B; Menkes CJ Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061 [TBL] [Abstract][Full Text] [Related]
36. Pharmacotherapy of Raynaud's phenomenon. Belch JJ; Ho M Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818 [TBL] [Abstract][Full Text] [Related]
37. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis]. Serri J; Legré R; Veit V; Guardia C; Gay AM Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894 [TBL] [Abstract][Full Text] [Related]
38. Clinical and image improvement of Raynaud's phenomenon after botulinum toxin type A treatment. Zhao H; Lian Y Australas J Dermatol; 2015 Aug; 56(3):202-5. PubMed ID: 25817568 [TBL] [Abstract][Full Text] [Related]
39. Phosphodiesterase inhibitors in Raynaud's phenomenon. Levien TL Ann Pharmacother; 2006; 40(7-8):1388-93. PubMed ID: 16835313 [TBL] [Abstract][Full Text] [Related]
40. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma. Colakoğlu M; Cobankara V; Akpolat T Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]